Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.

Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC, Anderson KC.

J Cell Biochem. 2007 Jul 1;101(4):950-68. Review.

PMID:
17546631
2.

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions.

Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC.

Eur J Cancer. 2006 Jul;42(11):1564-73. Epub 2006 Jun 9. Review.

PMID:
16765041
3.

Antimyeloma activity of heat shock protein-90 inhibition.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC.

Blood. 2006 Feb 1;107(3):1092-100. Epub 2005 Oct 18.

4.

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL.

Cancer Cell. 2004 Mar;5(3):221-30.

5.

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC.

Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5. Epub 2003 Dec 26.

6.

Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.

Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KC.

Cancer Res. 2003 Oct 15;63(20):6689-96.

7.

CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.

Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, Mitsiades CS, Mitsiades NS, Szczepek AJ, Ellman L, Harmon D, Grossbard ML, Anderson KC.

J Immunother. 2002 Jan-Feb;25(1):72-81.

PMID:
11924912
8.

Skin manifestations of Cushing disease in children and adolescents before and after the resolution of hypercortisolemia.

Stratakis CA, Mastorakos G, Mitsiades NS, Mitsiades CS, Chrousos GP.

Pediatr Dermatol. 1998 Jul-Aug;15(4):253-8.

PMID:
9720685
9.

Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report.

Mastorakos G, Mitsiades NS, Doufas AG, Koutras DA.

Thyroid. 1997 Jun;7(3):433-9.

PMID:
9226216
10.

Dopamine affects the in vitro basal secretion of rat placenta opioids in an opioid and dopamine receptor type-specific manner.

Stratakis CA, Mitsiades NS, Chrousos GP, Margioris AN.

Eur J Pharmacol. 1996 Nov 7;315(1):53-8.

PMID:
8960864
11.

Recurring oral giant cell lesion in a child with X-linked hypophosphatemic rickets: clinical manifestation of occult parathyroidism?

Stratakis CA, Mitsiades NS, Sun D, Chrousos GP, O'Connell A.

J Pediatr. 1995 Sep;127(3):444-6. Review.

PMID:
7658280

Supplemental Content

Loading ...
Support Center